

General Information

Name: Prof. Dr. med. Jan Krönke
Date of Birth: 05.05.1979
Gender: Male
Address: Department for Hematology, Oncology and Tumorimmunology
Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin
Hindenburgdamm 30, 12203 Berlin
Germany Phone: +49-030-450-613564
E-Mail: jan.kroenke@charite.de
Current Position: Professor for Hematologic Malignancies, Emmy-Noether Group Leader

Academic Education

1999-2006 Medical School, Ruprecht-Karls-University Heidelberg, Germany

Academic Degrees

2020 W2-Professorship for Hematologic Malignancies, Charité Berlin
2018 *Venia Legendi* Internal Medicine
2006 Medical Thesis (Molecular Virology, University of Heidelberg, Germany), grade *summa cum laude*
2006 Medical Exam and Approbation, Ruprecht-Karls-University Heidelberg, Germany
1998 Abitur (High school degree), Theodor-Heuss-Gymnasium, Göttingen, Germany

Professional Experience

2017 Board certification for Internal Medicine, Hematology, and Oncology
Since 2015 Emmy Noether Research Group Leader (DFG), University Hospital Ulm, Department of Internal Medicine III
2014-2015 Physician-Scientist Fellowship (Else-Kröner Fresenius Kolleg Ulm), University Hospital Ulm, Department of Internal Medicine III
2011-2014 Research Fellow at the Brigham and Women's Hospital/ Harvard Medical School, Laboratory of Prof. Dr. Benjamin L. Ebert, MD/PhD (DFG Research Fellowship)
2007-2011 Research Fellow at the University Hospital Ulm, Department of Internal Medicine III, Laboratory of Prof. Dr. Konstanze Döhner
2006-2017 Residency in Internal Medicine and Hematology/Oncology at the University Hospital Ulm, Department of Internal Medicine III (Director: Prof. Dr. Hartmut Döhner)
2002-2004 Doctoral student at the Ruprecht-Karls-University Heidelberg, Molecular Virology, Laboratory of Prof. Dr. Ralf Bartenschlager

Miscellaneous

Awards / Honors / Positions:

2017 Familie Kasprzak-Forschungspreis, Heidelberg University
2016 Paul-Martini-Preis
2015 Artur-Pappenheim-Preis, Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO)
2015 Württembergischer Krebspreis, Bayer-Stiftung
2015 Franziska-Kolb Award for Leukemia Research
Since 2015 Emmy Noether Research Program (DFG Kr3886/2-1)
2014-2015 Physician Scientist Fellowship, Else-Kröner Forschungskolleg

2011-2014

Research Fellowship, Deutsche Forschungsgemeinschaft (DFG Kr3886/1-1)

Publications

1. Meyer T, Jahn N, Lindner S, Röhner L, Dolnik A, Weber D, Scheffold A, Köpff S, Paschka P, Gaidzik VI, Heckl D, Wiese S, Ebert BL, Döhner H, Bullinger L, Döhner K, Krönke J. Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). **Leukemia**. 2019 Oct 1. [Epub ahead of print]
2. Cocciardi S, Dolnik A, Kapp-Schwörer S, Rücker FG, Lux S, Blätte TJ, Skambraks S, Krönke J, Heidel FH, Schnöder TM, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Döhner H, Bullinger L*, Döhner K*. Clonal evolution patterns in acute myeloid leukemia with *NPM1* mutation. **Nature Commun**. 2019;10(1):2031. *Equal contribution
3. Steinebach C, Kehm H, Lindner S, Vu LP, Köpff S, López Mármol Á, Weiler C, Wagner KG, Reichenzeller M, Krönke J†, Gütschow M†. PROTAC-mediated crosstalk between E3 ligases. **Chem Commun**. 2019;55(12):1821-24. †Corresponding authors
4. Steinebach C, Lindner S, Udeshi ND, Mani DC, Kehm H, Köpff S, Carr SA, Gütschow M†, Krönke J†. Homo-PROTACs for the Chemical Knockdown of Cereblon. **ACS Chem Biol**. 2018;13(9):2771-82. †Corresponding authors
5. Krönke J*†, Kuchenbauer* F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S*, Langer C*†. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). **Leukemia**. 2017;31(6):1363-67. *Equal contribution, †Corresponding authors
6. Krönke J*, Fink E*, Hollenbach P, MacBeth K, Hurst S, Udeshi N, Chamberlain P, Mani D, Man H, Gandhi A, Svinkina T, Schneider R, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers B, Carr S, Chopra R, Ebert B. Lenalidomide induces ubiquitination and degradation of casein kinase 1A1 in del(5q) MDS. **Nature**. 2015;523(7559):183-8. *Equal contribution
7. Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. **Science**. 2014;343(6168):301-5.
8. Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K. Clonal evolution in relapsed *NPM1*-mutated acute myeloid leukemia. **Blood**. 2013;122(1):100-8.
9. Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwien K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K. Monitoring of minimal residual disease in *NPM1*-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. **J Clin Oncol**. 2011;29(19):2709-16.
10. Bullinger L*, Krönke J*, Schön C*, Radtke I, Urlbauer K, Botzenhardt U, Gaidzik V, Carió A, Senger C, Schlenk RF, Downing JR, Holzmann K, Döhner K, Döhner H. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. **Leukemia**. 2010;24(2):438-49. *Equal contribution

Patents

1. KNOCK-IN RODENT COMPRISING A MUTATION IN AN ENDOGENOUS CRBN LOCUS AND METHODS OF USE THEREOF. Publication number: 20160338326; Application Number: 15/074,920. Filed: March, 18 2016; Publication date: November 24, 2016
2. COMPOSITIONS AND METHODS FOR SELECTING A TREATMENT FOR B-CELL NEOPLASIAS. Publication number: 20160282354; Application Number: 15/034,490. Filed: November 7, 2014; Publication date: September 29, 2016